Invest in LifeBridge Innovations, PBC

Transforming metastatic cancer from a terminal prognosis to a manageable disease like diabetes

EARLY BIRD TERMS: $265,788 LEFT

$3,842,111

raised from 33 investors
INVESTMENT TERMS
Priced Round
 $26.71M  $21.31M pre-money valuation
Early Bird Bonus: The first $349.999K of investments will be at $0.83 per share and a $21.317M pre-money valuation
Pitch Video
Investor Panel

Highlights

1
Team has 60 devices through FDA, products in 3000 hospitals, 300 yrs combined experience
2
Med tech firm sent unsolicited offer to buy us -investor/team unanimously agreed too early to sell
3
Granted patents in U.S., Canada, MX, EU, Japan, China, Australia, New Zealand, India, Chile
4
$5M raised from friends & family, angels, who know our track record & see a huge market opportunity

Featured Investors

Invested $200,000

Practicing physician and an Assistant Clinical Professor with the Texas Tech University Health Sciences Center for 30 years. Tech and biotechnology investor. Identified 3 early-stage investments which have reached over a $1B USD valuation


“The LifeBridge ATTF is the only technology that I have found which can treat millions of people with metastatic cancer who have exhausted all other therapies.”

View Investment Memo
Invested $200,000

James (Jim) LaBate is a seasoned investor with over 35 years in the finance and investment fields, including more than 30 years between Merrill Lynch and Morgan Stanley. Mr. LaBate managed a portfolio of public equity and debt securities among other asset


“The top 5 reasons I invested $200,000 into LifeBridge Innovations - Jim LaBate”

[object Object] profile photo

Other investors include

 & 107 more


Our Team

CEO and Founder
He has a BA in communication from UCF. His first company was a medical ed firm that sold materials he created. He designed a marketing program that sold the training products to 3,000 hospitals.
Lee Zehngebot M.D.Medical Advisor
Dr. Lee Zehngebot served as the Director of Clinical Research, Advent Cancer Institute in Orlando for over 10 years and has participated as Principal Investigator and Co-Investigator on numerous clinical studies. Medical advisor to the company
Zeev Bomzon PhDLead Scientist
Former Director of Science for Novocure, the original developers of TTF, led a team of 15 physicists and engineers. Named on over 25 patents, over 30 scientific articles published in major journals. Authored text book writeup on tumor treating fields.

Pitch



















Future projections are not guaranteed










Overview